Disclaimer

Information presented on this forum is designed for educational and informational purposes only. The information provided is not a substitute for professional, medical and health advice. Do not interpret or use this information to diagnose or treat a health problem or disease without consulting a professionally qualified health care provider. Please consult a relevant health care provider if You have any questions or concerns or if You wish to determine the information You are relying on is appropriate for Your medical condition/s.

Clinuvel does not endorse or attest to the validity or accuracy of any treatments or medications mentioned. Clinuvel makes no representations concerning the efficacy or suitability of any treatments, medications or products on this forum or website.

Clinuvel has made every effort to ensure the accuracy of information on this forum and welcomes Your feedback on any information. All feedback should be sent to the "Contact us" section. Clinuvel is not responsible or liable for any errors or omissions that may be found in the information provided or for the results obtained from the use of such information. Clinuvel encourages You to consult any other source and verify and confirm the information contained in any of the information, databases or pages accessible within or from this forum.

Further disclaimers apply to emails and Clinuvel announcements.

Clinuvel Blog Posts

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Read More

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...

Read More

Clinuvel Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Clinuvel Spotlight

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

Read more